Loading
HA
Harvard Apparatus Regenerative Technology, Inc. Stock: price and insider trades · United States
1 insider bought €340k of shares over the last 90 days, the latest by He Junli, filed 25 Sept 2026.
Harvard Apparatus Regenerative Technology, Inc.: what insiders have been doing
Harvard Apparatus Regenerative Technology, Inc., classified in the Food & Beverage sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (23 October 2025 to 23 October 2026), 4 filings came from 1 insider.
Only purchases show up on the open market, 3 purchases in all worth €344k, filed by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 chief executive among the declarants. He Junli filed the largest purchase, €327k, on 25 September 2026, which represents 0.81% of the company's market value.
Compared with its exchange (279 companies, median 8 filings), a count of 4 filings is below the norm. Looking back to 2016, when coverage begins, insiders filed 50 purchases and 4 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 704,000 USD and net income at -6.9 m USD.
The last insider purchase was made public on 25 September 2026, 29 days ago. Typically, a trade is published a median of 12 days after it takes place. Section 16 rules allow two business days to file each Form 4.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
75
Thresholds
n/a
Buy Volume
€4M
50 ops. · all time
Sell Volume
€919,709
4 ops. · all time
Who traded when
BuySaleJunli He7 buys
Since the insiders bought
- -8.4%Entry US$2.15 · Close 22 Oct 2026 US$1.97
- -41.4%Entry US$4.35 · Close at T+365 US$2.55
- -50.8%Entry US$6.08 · Close at T+365 US$2.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.20
Analyst consensus
Income statement
RevenueUS$704k
Gross profitUS$58k8% margin
EBITDA-US$6.8M-960% margin
Net income-US$6.9M-975.7% margin
Valuation
Beta-0.39
Balance sheet & cash
Market capUS$44.6M
Total debtUS$199k
Free Cash Flow-US$3.8M
Profitability & ownership
ROA-219.5%
% insiders38.9%
% institutions0.0%
Last declaration on 25 September 2026
Declarations75 total
683,725 shares@ US$1.051.53% mcap56.7% of flowCommon StockSEC:0001437749-26-031181:0
361,905 shares@ US$1.050.81% mcap30.0% of flowCommon StockSEC:0001437749-26-031181:1
Canonical exit: 10 Dec 2026 (T+90)
6,725 shares@ US$2.150.031% mcap1.1% of flowCommon StockSEC:0001437749-26-031181:2
Canonical exit: 14 Dec 2026 (T+90)
3,000 shares@ US$1.700.4% of flowCommon StockSEC:0001437749-25-036518:0
Canonical exit: 23 Feb 2026 (T+90)
300 shares@ US$1.980.0% of flowCommon StockSEC:0001437749-25-030204:0
Canonical exit: 29 Dec 2025 (T+90)
11,225 shares@ US$1.851.6% of flowCommon StockSEC:0001437749-25-029783:0
Canonical exit: 1 Dec 2025 (T+90)
4,050 shares@ US$1.720.6% of flowCommon StockSEC:0001437749-25-028095:0
Canonical exit: 19 Nov 2025 (T+90)
2,299 shares@ US$2.870.6% of flowCommon StockSEC:0001437749-25-000007:0
Canonical exit: 24 Mar 2025 (T+90)
5,101 shares@ US$3.371.4% of flowCommon StockSEC:0001493152-24-036024:0
Canonical exit: 25 Nov 2024 (T+90)
1,600 shares@ US$2.800.4% of flowCommon StockSEC:0001493152-24-025927:0
Canonical exit: 19 Sept 2024 (T+90)
2,700 shares@ US$4.761.1% of flowCommon StockSEC:0001493152-24-000226:0
Canonical exit: 26 Mar 2024 (T+90)
900 shares@ US$4.920.4% of flowCommon StockSEC:0001493152-23-045302:0
Canonical exit: 13 Mar 2024 (T+90)
1,500 shares@ US$5.070.6% of flowCommon StockSEC:0001493152-23-044357:0
Canonical exit: 5 Mar 2024 (T+90)
1,500 shares@ US$5.430.7% of flowCommon StockSEC:0001493152-23-032876:0
Canonical exit: 10 Dec 2023 (T+90)
3,400 shares@ US$4.691.4% of flowCommon StockSEC:0001493152-23-031566:0
Canonical exit: 26 Nov 2023 (T+90)
8,000 shares@ US$4.322.9% of flowCommon StockSEC:0001493152-23-030317:0
Canonical exit: 16 Nov 2023 (T+90)
6,864 shares@ US$4.35100.0% of flowCommon StockSEC:0001493152-23-030013:0
Canonical exit: 19 Nov 2023 (T+90)
62,500 shares@ US$6.0022.9% of flowCommon StockSEC:0001493152-23-011747:0
Canonical exit: 5 Jul 2023 (T+90)
135 shares@ US$6.83100.0% of flowCommon StockSEC:0001415889-23-000497:0
83,676 shares@ US$7.1744.3% of flowCommon StockSEC:0001415889-22-012348:1
1,952 shares@ US$7.170.4% of flowCommon StockSEC:0001415889-22-012350:1
48,532 shares@ US$7.1750.0% of flowCommon StockSEC:0001415889-22-012347:1
7,000 shares@ US$2.000.9% of flowCommon StockSEC:0001415889-22-012350:0
300,000 shares@ US$2.00100.0% of flowCommon StockSEC:0001415889-22-012348:0
174,000 shares@ US$2.00100.0% of flowCommon StockSEC:0001415889-22-012347:0
25 of 75 declarations
About Harvard Apparatus Regenerative Technology, Inc.
Harvard Apparatus Regenerative Technology, Inc. is a company focused on developing regenerative technologies for medical applications. It aims to create innovative solutions for regenerative medicine.
